4299L Pretest: Cutting Edge of Transplantation Transplant Summit 2024: Leveraging Innovative Technology To Save and Improve More Lives Through Transplantation

Pretest

Cutting Edge of Transplantation Transplant Summit 2024: Leveraging Innovative Technology To Save and Improve More Lives Through Transplantation

February 22-24, 2024

Arizona Biltmore, Phoenix, AZ

Please complete these pretest questions so we can assess your knowledge and confidence prior to attending CEoT 2024. You are not required to pass the pretest - it is simply to measure knowledge and confidence prior to the activity.

Question Title

* 1. I am a:

PharmD

Other (please specify)

Question Title

* 2. Prior to the start of this activity, I feel I am able to:

	Strongly agree	Agree	Disagree	Strongly Disagree
Define the current advanced technologies available for improving the delivery of medical care to patients.	Define the current advanced technologies available for improving the delivery of medical care to patients. Strongly agree	Define the current advanced technologies available for improving the delivery of medical care to patients. Agree	Define the current advanced technologies available for improving the delivery of medical care to patients. Disagree	Define the current advanced technologies available for improving the delivery of medical care to patients. Strongly Disagree
Identify those technologies that have or may have a future role in the care of transplant patients.	Identify those technologies that have or may have a future role in the care of transplant patients. Strongly agree	Identify those technologies that have or may have a future role in the care of transplant patients. Agree	Identify those technologies that have or may have a future role in the care of transplant patients. Disagree	Identify those technologies that have or may have a future role in the care of transplant patients. Strongly Disagree
Describe novel strategies of using currently existing technology to advance the field of transplantation.	Describe novel strategies of using currently existing technology to advance the field of transplantation. Strongly agree	Describe novel strategies of using currently existing technology to advance the field of transplantation. Agree	Describe novel strategies of using currently existing technology to advance the field of transplantation. Disagree	Describe novel strategies of using currently existing technology to advance the field of transplantation. Strongly Disagree
Discuss the regulatory and ethical challenges associated with the implementation of new technologies in the care of transplant patients.	Discuss the regulatory and ethical challenges associated with the implementation of new technologies in the care of transplant patients. Strongly agree	Discuss the regulatory and ethical challenges associated with the implementation of new technologies in the care of transplant patients. Agree	Discuss the regulatory and ethical challenges associated with the implementation of new technologies in the care of transplant patients. Disagree	Discuss the regulatory and ethical challenges associated with the implementation of new technologies in the care of transplant patients. Strongly Disagree

Question Title

* 3. Technological advances in solid organ transplantation include all of the following except:

A. 3D printed livers and hearts for transplantation

B. Genetically modified pig organs

C. Management apps for post-transplant care

D. Perfusion device for donated lungs of suboptimal quality

Question Title

* 4. Genetic modification of donor kidneys using CRISPR gene editing has the following benefits:

A. Reduced risk of rejection compared to wild type pig kidneys

B. Longer graft survival in non-human primate studies compared to wild type pig kidneys

C. Inactivation of porcine endogenous retrovirus (PERV)

D. A and B

E. A, B, and C

Question Title

* 5. Deep learning, a form of artificial intelligence (AI) can potentially be utilized for patient care among solid organ transplant recipients in the following ways. Please select the single best answer.

A. AI enhanced ECGs (using deep learning) have replaced blood testing methods (GEP & dd-cfDNA) when screening for cardiac allograft rejection.

B. AI enhanced ECGs (using deep learning) are known to be superior to endomyocardial biopsy for the diagnosis of acute cellular rejection (ACR) and antibody mediated rejection (AMR).

C. AI enhanced ECGs (using deep learning) have been demonstrated to be effective in detecting moderate-severe acute cellular rejection (ACR) among heart transplant recipients.

D. All of the above.

E. A and B only.

Question Title

* 6. Which of the following best describes the promise of artificial intelligence (AI) in liver transplantation?

A. AI primarily focuses on replacing human decision-making in liver transplantation with fully automated processes.

B. AI is limited by its inability to process the complex data associated with liver transplantation, making it less useful than traditional methods.

C. AI promises to enhance clinical decision-making by helping to decipher complex data and inform on aspects such as immune modulator networks, dynamic pharmacokinetics, and organ allocation.

D. The use of AI in liver transplantation has been shown to significantly improve postoperative graft survival rates.

Question Title

* 7. After transplantation, is physical activity in recipients expected to:

A. Sharply improve and continue in an upwards trajectory

B. Continue along its pre-transplant trajectory

C. Initially decline, and then slowly improve

D. Initially decline, and then rapidly improve

Question Title

* 8. What approach would not be considered a method to prototype and test new decision support materials for patients?

A. Hand sketches of a concept

B. Showing digital mockups to users

C. Press release about the public launch

D. Observing users trying out the materials

Question Title

* 9. CG is a 52 year old male with alcohol-associated liver disease (AALD) who is a candidate for early liver transplantation (transplantation without period of sobriety). Patients who are at lower risk for continued alcohol use are prioritized. Therefore, predicting the risk of continued alcohol post-transplant using objective criteria is important for improving fairness and efficiency in organ allocation. Algorithm-development research has associated factors that predict an increased risk of continued alcohol consumption. These include: consuming more than ten drinks/day at the time of hospitalization, previous abuse of illicit substances, previous alcohol-related legal issues, and multiple failed rehabilitation attempts. To improve fair and efficient organ allocation, information regarding which of the following should be included CG's evaluation?

A. alcohol consumption at the time of hospitalization

B. history of legal problems associated with alcohol use

C. marital history

D. None of the above

E. A and B

F. All of the above

Question Title

* 10. Novel drug delivery systems already utilized in transplantation include which systems?

A. Antibody humanization or modifications

B. Protective polymer coating with controlled release

C. Nanoparticle delivery

D. Topical agent delivery

Question Title

* 11. Known benefits of normothermic liver perfusion devices include all the following except:

A. Improved preservation of fatty donor livers

B. Improved preservation of older donor livers

C. Less ischemic cholangiopathy following DCD donor liver transplantation

D. Less reperfusion syndrome intraoperatively in recipient

E. Lower cost

Question Title

* 1. I am a:

Question Title

* 2. Prior to the start of this activity, I feel I am able to:

Question Title

* 3. Technological advances in solid organ transplantation include all of the following except:

Question Title

* 4. Genetic modification of donor kidneys using CRISPR gene editing has the following benefits:

Question Title

* 5. Deep learning, a form of artificial intelligence (AI) can potentially be utilized for patient care among solid organ transplant recipients in the following ways. Please select the single best answer. ​

Question Title

* 6. Which of the following best describes the promise of artificial intelligence (AI) in liver transplantation?

Question Title

* 7. After transplantation, is physical activity in recipients expected to:

Question Title

* 8. What approach would not be considered a method to prototype and test new decision support materials for patients?

Question Title

Question Title

* 10. Novel drug delivery systems already utilized in transplantation include which systems?

Question Title

* 11. Known benefits of normothermic liver perfusion devices include all the following except:

* 5. Deep learning, a form of artificial intelligence (AI) can potentially be utilized for patient care among solid organ transplant recipients in the following ways. Please select the single best answer.